Sanofi’s new chief executive, Belén Garijo, says she is taking a close look at the company’s late-stage pipeline as the French drugmaker continues to streamline its clinical portfolio. The review comes as Garijo steps into leadership after leaving Germany’s Merck KGaA, inheriting a business that clearly needs a strategic reset.
The focus on late-stage programs matters because those assets are typically the closest to delivering future growth. By examining that part of the pipeline in depth, Garijo appears to be signaling that Sanofi wants to be more selective about which development candidates deserve continued investment and which ones no longer fit the company’s priorities.
The latest comments also suggest that the ongoing clinical clearout is part of a broader effort to improve execution rather than a one-off move. For investors and industry watchers, the key question is whether a tighter pipeline strategy can help Sanofi reverse recent disappointment and sharpen its path toward more reliable product launches.
Garijo’s early message is that Sanofi is reassessing what it has, where it can compete most effectively, and how to rebuild confidence in its drug development engine. While full details of the overhaul have yet to emerge, the emphasis on the late-stage pipeline shows where the company believes the most immediate strategic decisions need to be made.
